LUNGevity: ALK-positive Lung Cancer Research Award Program (LOI)

The goal of the RFA is to fund impactful proposals in the ALK-positive lung cancer space. Suggested areas of investigation may include (but are not restricted to) the following:

1. Projects that aim to understand novel treatment options. A novel treatment option may be a new monotherapy option or combination approaches
2. Projects that aim to identify existing biomarkers that predict both sensitivity to specific therapies and timing of relapse on therapy

Funding mechanisms:

-Transformational Award: up to $500,000 over 2 years

-Clinical Trial Innovation Award: up to $750,000 over 2 years

Please contact Research Authority if planning to submit: Overhead 10%.

Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution. All research funds will be disbursed through a U.S. institution

https://lungevity.org/our-research/translational-science-research-grant-programs/2020-alk-positive-lung-cancer-research